Solicitations

0
Awards
0
Pulled from the Basket
0
Estimated Value of Projects
0
Total Funding Awarded
How Does This Work?

JPM-MCS, and other customers (DTRA/JSTO, etc.), offers funding opportunities to MCDC members through solicitations called Requests for Prototype Proposals (RPPs). The RPPs offer MCDC members the opportunity to propose prototype technologies to the technology requirements in each solicitation’s sub-objective area. Active and Forecasted solicitations are listed below, as are the status of RPPs for which submissions have been received.

If you are not a MCDC member and wish to become one, please click here for instructions.

RPP Release #
(Date)
RequirementRequiring OfficeSubmission TypeSubmission Due Date
RPP-20-03
(1/28/2020)
20-03: INATS - Soman Nerve Agent Pre-Treatment Pyridostigmine Bromide (SNAPP) Shelf-life ModernizationJPM-CBRN-Medical2/26/2020
Noon Eastern
RPP-20-01
(11/8/2019)
20-01: TRE: Small Molecule Antiviral Therapeutic Medical CountermeasuresJPEO-CBRNDWhite Paper
Full Proposal
Closed
03/06/2020
Noon ET

Received: # of proposals received
Selected: # of proposals selected for award at time of Selection Announcement Letter
Basket: # of proposals placed in basket
*Proposal pulled from basket for award

*Awarded: Full Executed Project Agreements (Prime Awardee Listed Only)
*In Evaluation:  Government is performing Source Selection
*In Negotiation:  Government has made selections and Offerors have been notified. SOW development and negotiations are on-going.

RPP Release # (Date)RequirementRequiring OfficeSubmission StatusAwardeeAward DateEstimated Value
RPP-20-02
(11/20/2019)
20-02: TRE: INATS - Centrally Acting Medical Countermeasure for Nerve Agent ExposureJPM CBRN MedicalReceived:
Selected:
Basket:
In Evaluation
RPP-19-12
(9/10/2019)
19-12: Phase 1 Clinical Dose Escalation Study of BoNT mAb G03-52-01 DPJPM CBRN MedicalReceived: 1
Selected: 1
Basket: 0
In Negotiation
RPP-19-11
(7/3/2019)
19-11: Therapeutic Evaluation of 3,4-Diaminopyridine (3,4-DAP)JPM CBRN MedicalReceived: 3
Selected: 1
Basket: 1
In Negotiation
RPP-19-10
(4/30/2019)
19-10: Development of a Scopolamine Auto Injector PrototypeJPM CBRN MedicalReceived: 5
Selected: 1
Basket: 3
Aktivax2/21/2020$24,466,039
RPP-19-09
(3/26/2019)
19-09: In Vitro Affinity-based Diagnostic System for Diseases Resulting from Chemical, Biological, and Radiological Exposure (IADS)JPM CBRN MedicalReceived: 9
Selected: 2
Basket: 2
University of North Carolina10/23/2019$11,988,615
RPP-19-08
(3/1/2019)
19-08: Medical Countermeasure Prototype Development to Biological Toxins (PRE)DTRAReceived: 3
Selected:
Basket: 2
No Awards Made
RPP-19-07
(1/31/2019)
19-07: Natural Product Chemical Medical CountermeasuresJPM CBRN MedicalReceived: 1
Selected: 0
Basket: 0
No Awards Made
RPP-19-06
(1/31/2019)
19-06: Novel and Innovative Prophylaxis/Pretreatment Medical Countermeasures (MCMs) to Protect the U.S. Warfighter Against Adverse Effects of Organophosphorus Nerve Agents (OPNAs)JPM CBRN MedicalReceived: 5
Selected: 1
Basket: 1
In Negotiation
RPP-19-05
(1/31/2019)
19-05 (TRE):
Prophylactic and Therapeutic cMCM Libraries, Mid to Late Pipeline Development
JPM CBRN MedicalReceived: 6
Selected: 1
Basket: 3
*Alchem Laboratories
MRI Global

*MRI Global
11/21/2019

12/03/2019

12/23/2019
$13,371,881

$14,548,813

$12,472,695
RPP-19-04
(12/19/2018)
19-04 (PRE): Ebola Vaccine Prototype
JPM CBRN MedicalReceived: 1
Selected: 1
Basket: 0
The Albert B. Sabin Vaccine Institute9/12/2019$8,558,226
RPP-19-03
(11/1/2018)
19-04 (TRE): Development of Naloxone Auto-injectorJPM CBRN MedicalReceived: 6
Selected: 1
Basket: 2
Kaleo, Inc.7/29/2019$18,640,349
RPP-19-03
(11/1/2018)
19-03 (TRE): Development of Diazepam Auto-injectorJPM CBRN MedicalReceived: 6
Selected: 1
Basket: 3
Emergent BioSolutions9/17/2019$21,309,825
RPP-19-02
(12/4/2018)
19-02 (TRE/PRE): Development and Testing of a Rapid Response Antibody (Ab) Platform System and the Accelerated Development of a Safe and Efficacious Prototype Medical Countermeasure (MCM) Against a Biodefense Threat of InterestJPM CBRN MedicalReceived: 6
Selected: 2
Basket: 3
SAB Biotherapeutics Inc.

Ology
8/7/2019

8/30/2019
$25,080,626

$30,203,022
RPP-19-01
(11/20/2018)
19-01 (TRE): Development of an FDA-Approved Smallpox Medical Countermeasure for a Post-Exposure Prophylaxis IndicationJPM CBRN MedicalReceived: 1
Selected: 1
Basket: 0
SIGA Technologies7/2/2019$19,507,304
RPP-18-09
(8/8/2018)
18-22 (PRE): Walter Reed Army Institute of Research Viral Disease Branch (WRAIR, VDB), Good Manufacturing Practices (GMP) Development of Dengue Purified Inactivated VaccinesJPM CBRN MedicalReceived:
Selected:
Basket:
Requirement Canceled
RPP-18-06
(3/23/2018)
18-17 (PRE): Marburg Virus Vaccine DevelopmentDTRA
JSTO
Received: 3
Selected: 1
Basket: 2
*International AIDS Vaccine Initiative10/15/2019$35,751,818
RPP-18-06
(3/23/2018)
18-16 (TRE): Novel Therapeutics for Multidrug Resistant Bacterial Bio threat PathogensDTRA
JSTO
Received: 5
Selected: 1
Basket: 2
Battelle3/1/2019$8,894,774
RPP-18-05
(4/12/2018)
18-19 (PRE): Development and utilization a monoclonal antibody platform prototype for development of monoclonal antibodies as medical countermeasures against threats of interest. Aerosolized Plague infection is the subject of this requirement.JPM CBRN MedicalReceived: 2
Selected: 1
Basket: 0
Ology Bioservices3/22/2019$130,267,841
RPP-18-04
(4/5/2018)
18-15 (DET): Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the PlagueDTRA
JSTO
Received: 3
Selected: 2
Basket: 0
Inbios International

Brimrose Technology Corp
8/27/18

9/24/2018
$4,436,864

$1,319,680
RPP-18-04
(4/5/2018)
18-14 (PRE): Next Generation Devices for Delivery of Nucleic Acid VaccinesDTRA
JTSO
Received: 4
Selected: 2
Basket: 4
*Inovio Pharmaceuticals
*PharmaJet
6/6/2019

6/17/2019
$8,149,588

$9,551,401
RPP-18-04
(4/5/2018)
18-13 (PRE): Prophylaxis / Pretreatment Against Francisella tularensisDTRA
JTSO
Received: 4
Selected: 1
Basket: 2
*University of New Mexico
*Southwest Research Institute
9/26/2019

11/5/2019
$7,549,230

$18,287,542
RPP-18-04
(4/5/2018)
18-12 (PRE): Francisella tularensis Immune AssaysDTRA
JTSO
Received: 3
Selected: 0
Basket: 3
No Award Made at This Time
RPP-18-04
(4/5/2018)
18-11 (PRE): Burkholderia Species Immune AssaysDTRA
JTSO
Received: 5
Selected: 0
Basket: 4
*University of Nevada, Reno9/12/2019
$2,505,186
RPP-18-04
(4/5/2018)
18-10 (DET): Assay Development for the Identification of Markers of Venezuelan Equine Encephalitis Virus Infection in Animal ModelsDTRA
JTSO
Received: 2
Selected: 1
Basket: 1
Meso Scale Diagnostics4/30/2019$2,709,021
RPP-18-04
(4/5/2018)
18-09 (DET): Multiplex Vertical flow Paper-based Immunoassay (VPI) Diagnostic SystemDTRA
JTSO
Received: 2
Selected: 0
Basket: 1
No Award Made at This Time
RPP-18-03
(2/9/2018)
18-08 (TRE): Proof of Concept Formulations for CBRN Medical Countermeasures to be administered via AutoinjectorDTRA
JTSO
Received: 5
Selected: 2
Basket: 2
SRI International

Emergent BioSolutions
3/4/2019

3/4/2019
$1,940,766

$2,236,389
RPP-18-03
(2/9/2018)
18-07 (TRE): Discovery and Development of New Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve AgentsDTRA
JSTO
Received: 1
Selected: 1
Basket: 0
Southwest Research Institute3/18/2019$10,037,014
RPP-18-03
(2/9/2018)
18-06 (PRE): Enhanced circulatory stability and GMP manufacturing of phosphotriesterase (PTE) / organophosphorous hydrolase (OPH) variants as prophylaxis against a broad-spectrum of organophosphorus nerve agents (OPNAs)DTRA
JSTO
Received: 1
Selected: 1
Basket: 0
BioHybrid6/20/2019$30,249,814
RPP-18-02
(1/10/2018)
18-05 (TRE): Development of a Food and Drug Administration (FDA)-approved medical countermeasure (MCM) for treatment of multi-drug resistant bacterial biological warfare agents delivered via an aerosol route of exposureJPM CBRN MedicalReceived: 1
Selected: 0
Basket: 1
No Award Made at This Time
RPP-18-02
(1/10/2018)
18-04 (TRE): Relevant Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic EvaluationsJPM CBRN MedicalReceived: 2
Selected: 1
Basket: 1
SciTech Services9/12/2018$235,797
RPP-18-01
(10/19/2017)
18-03 (TRE): Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve AgentsDTRA
JSTO
Received: 1
Selected: 1
Basket: 0
Leidos8/16/2018$10,966,574
RPP-18-01
(10/19/2017)
18-02 (DET): Development of Multiplex Molecular Diagnostics Based on CRISPR-Cas and other Synthetic Biology ApproachesDTRA
JSTO
Received: 0
Selected:
Basket:
No Award Made
RPP-18-01
(10/19/2017)
18-01 (DET): Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial AgentDTRA
JSTO
Received: 6
Selected: 2
Basket: 0
California Institute of Technology
General Electric
12/4/2018

12/13/2018
$3,387,096

$5,997,583
RPP-17-03
(6/17/2017)
17-08: Chemical Exposure In Vitro Diagnostics (ChemDx) JPM CBRN MedicalReceived: 3
Selected: 2
Basket: 1
MRI Global10/10/2018$9,653,670
RPP-17-03
(6/17/2017)
17-07: Man-Portable Diagnostics System (MPDS) – Expanded ScopeJPM CBRN MedicalReceived: 4
Selected: 1
Basket: 1
Cepheid8/24/2018$56,362,300
RPP-17-03
(6/17/2017)
17-06: Execution of Phase 1 Clinical Study for Venezuelan Equine Encephalitis (VEE) Monovalent Virus Replicon Particle (VRP) vaccineJPM CBRN MedicalReceived: 4
Selected: 0
Basket: 2
No Award Made at This Time
RPP-17-02
(2/13/2017)
17-05: Man-Portable Diagnostics System (MPDS)JPM CBRN MedicalReceived: 3
Selected: 1
Basket: 1
MRI Global9/1/2017$42,357,690
RPP-17-02
(2/13/2017)
17-04: Development of Multi-Target Single-Vector Vaccine Prototype against aerosolized Venezuelan Equine Encephalitis Virus (VEEV)JPM CBRN MedicalReceived: 1
Selected: 1
Basket: 0
Bavarian Nordic3/16/2018$37,979,997
RPP-17-02
(2/13/2017)
17-03: Development of Marburgvirus (MARV) Vaccine Prototype against aerosolized MARVJPM CBRN MedicalReceived: 2
Selected: 1
Basket: 1
Selectee did not execute Base Agreement
RPP-17-01
(1/13/2017)
17-02: Development of Efficacious Antiviral CountermeasuresJPM CBRN MedicalReceived: 5
Selected: 0
Basket: 2
*Mapp BioPharmaceuticals11/7/2017$40,831,616
RPP-17-01 (1/13/2017)17-01: Development of Monoclonal Antibody and Related Technologies as Medical Countermeasures against aerosolized Venezuelan Equine Encephalitis (VEE) VirusJPM CBRN MedicalReceived: 3
Selected: 0
Basket: 2
No Award Made at This Time
RPP-16-02
(7/15/2016)
16-06: Eastern Equine Encephalitis Virus Advanced Technology Demonstration (EEEV ATD)JPM CBRN MedicalReceived: 6
Selected: 0
Basket: 4
No Award Made at This Time
RPP-16-02
(7/15/2016)
16-05: Venezuelan equine encephalitis (VEE) Monovalent VLP Phase I Clinical StudyJPM CBRN MedicalReceived: 2
Selected: 1
Basket: 1
SRI International2/3/2017$4,922,193
RPP-16-02
(7/15/2016)
16-04: Lyophilized Formulation and Final Product Manufacturing Process for WEVEE VaccineJPM CBRN MedicalReceived: 1
Selected: 0
Basket: 1
No Award Made at This Time
RPP-16-02
(7/15/2016)
16-03: Development of a Dual Drug Delivery Device (D4) AutoinjectorJPM CBRN MedicalReceived: 5
Selected: 1
Basket: 2
Emergent BioSolutions7/25/2017$23,145,596
RPP-16-01
(6/22/2016)
16-02: Development of Monoclonal Antibody Medical Countermeasures against Aerozolized Botulinum Toxin Serotypes A and BJPM CBRN MedicalReceived: 1
Selected: 1
Basket: 0
Ology Bioservices9/30/2016$44,114,567
RPP-16-01
(6/22/2016)
16-01: Fill/Finish of Venezuelan Equine Encephalitis (VEE) virus like particle (VLP) Bulk Drug ProductJPM CBRN MedicalReceived: 3
Selected: 1
Basket: 1
SRI International12/8/2016$660,715